Using of checkpoint inhibitors as a treatment for melanoma

dc.contributor.author	Netfa, Khadija
dc.date.accessioned	2020-07-07T10:08:20Z
dc.date.available	2020-07-07T10:08:20Z
dc.date.issued	2020-02-18
dc.identifier.uri	http://repository.limu.edu.ly/handle/123456789/1723
dc.description	Immune checkpoint inhibitors are drugs that help the immune system to release “brakes” of inhibitory receptors expressed on the surface of activated T-cells, cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death receptor 1 (PD-1) that enhances T-cell-mediated antitumor immune responses leading to improved immune responses. Ipilimumab and Nivolumab are examples of immune checkpoint inhibitors, where ipilimumab targets CTLA-4 and nivolumab targets PD1/PD-L1	en_US
dc.description.abstract	Immune checkpoint blockade has used as a treatment of patients with advanced melanoma and many other cancers. Blockade of inhibitory receptors, cytotoxic Tlymphocyte antigen 4 (CTLA-4) and programmed cell death receptor 1 (PD-1) that enhances T-cell-mediated antitumor immune responses leading to improved immune responses, based on their studies and mechanism of action in the treatment of metastatic melanoma	en_US
dc.language.iso	en	en_US
dc.publisher	faculty of Basic Medical Science - Libyan International Medical University	en_US
dc.rights	Attribution 3.0 United States	*
dc.rights.uri	http://creativecommons.org/licenses/by/3.0/us/	*
dc.title	Using of checkpoint inhibitors as a treatment for melanoma	en_US
dc.type	Other	en_US

Except where otherwise noted, this item's license is described as Attribution 3.0 United States